Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.68 |
| ▸ | RAF1 | P04049 | 5/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897115 | 0.95 | MAPK14 (0.65) | MAPK14RAF1BRAF | |
| SCHEMBL5897202 | 0.91 | MAPK14 (0.58) | MAPK14RAF1BRAF | |
| SCHEMBL5897121 | 0.87 | MAPK14 (0.62) | MAPK14RAF1BRAF | |
| SCHEMBL7675279 | 0.87 | MAPK14 (0.65) | MAPK14RAF1BRAF | |
| SCHEMBL4829504 | 0.86 | MAPK14 (0.61) | MAPK14RAF1BRAF | |
| SCHEMBL4827685 | 0.86 | MAPK14 (0.60) | MAPK14RAF1BRAF | |
| SCHEMBL4831641 | 0.84 | MAPK14 (0.60) | MAPK14RAF1BRAF | |
| SCHEMBL5896972 | 0.84 | MAPK14 (0.56) | MAPK14RAF1BRAF | |
| SCHEMBL5897282 | 0.84 | MAPK14 (0.68) | MAPK14RAF1BRAF | |
| SCHEMBL4833606 | 0.84 | MAPK14 (0.58) | MAPK14RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | MAPK14 2563/4885RAF1 1028/4885BRAF 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.